Dyslipidemia is the most fundamental risk factor for atherosclerotic cardiovascular disease (ASCVD). In clinical practice, many commonly prescribed medications can alter the patient’s lipid profile and, potentially, the risk for ASCVD—either favorably or unfavorably. The dyslipidemia observed in type 2...
Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we...
(BUDCA) plays a significant positive role in safely reducing the serum LDL cholesterol concentration of individuals with a history of hypercholesterolemia, which is very important for the management of individuals at risk of atherosclerotic cardiovascular disease (ASCVD), such as myocardial infarction ...
ASCVD, atherosclerotic cardiovascular disease; CKD-MBD, chronic kidney disease-mineral and bone disorder; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HTN, hypertension; MRA, mineralocorticoid receptor antagonist; ns-MRA, nonsteroidal mineralocorticoid ...
Our opinion is that HTG may represent not only as a relevant contributor to ASCVD risk but may also play a role in the onset and progression of renal disease 21, 28. Although the underlying pathophysiological mechanisms responsible for TG-induced renal damage have yet to be completely understood...
Lp(a) is regarded as a risk factor for several cardiovascular diseases. Numerous epidemiological, clinical and in vitro studies showed a strong association between increased Lp(a) and atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve disease/aortic stenosis (CAVD/AS), stroke, ...